New shot aims to tame hepatitis b in early trial
NCT ID NCT06115993
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tests a new drug, AHB-137, given as a shot under the skin. It first checks safety in healthy volunteers, then tests how well it works in people with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can lower or clear the hepatitis B virus. About 129 people took part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanfang Hospital, Southern Medical University
Guangzhou, China
-
The First Hospital of Jilin University
Jilin, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Conditions
Explore the condition pages connected to this study.